Nanotechnology has become an outgrowing field in novel drug delivery system. It confers several merits over conventional formulations like increased solubility and bioavailability, targeted drug delivery and a decreased dose of the drug. The selection of appropriate method for the preparation of nanoparticulate system depends on the physicochemical characteristics of the drug to be loaded and polymer. This review has covered the most widely acceptable preparation techniques for polymeric and lipidic nanoparticles including nanoprecipitation, milling, extrusion, supercritical fluid technology, salting out, gelation, sonication, high-pressure homogenization, and solvent emulsification methods. Nanocarriers, the traditional nano-formulation drug delivery systems, encountered some major problems in process scale-up, reproducibility, and stability during storage. To circumvent these problems a new approach has emerged which are "In situ or self-assembled nanoparticles drug delivery system." Such approaches comprise experimentation with different types of polymers, surfactants or novel process in order to prepare a preconcentrate of drug formulation, which on entering into an aqueous medium (gastrointestinal fluid, blood) will form nanoparticles. The in situ nanoformulations can be the futuristic approach in nanocarriers to overcome the problems associated with the scale-up process and also minimize the cost of production. This review focuses on different preparation techniques for polymeric and lipidic nanocarriers preparation, in situ nanoformulation approaches and release characteristics of stimuli responsive nanoformulation.
INTRODUCTION
Commercially available conventional dosage forms are lacking for targeting the drug delivery and have a plethora of formulation problems. Many attempts have been made over a few decades in order to develop newer drug delivery systems that can overcome the problems faced by the existing dosage forms. Along with this, researchers were also trying to incorporate multidisciplinary scientific approaches to improve the drug's physicochemical limitations, bioavailability issues, site-specific delivery, and stability in the microenvironment. Additionally, efforts were made for preventing the dose dumping by controlling the release profile, reduced exposure of the drug to non-targeting tissues, increasing safety profile, and minimizing the toxicity and side effects.
Nanotechnology has driven drug delivery approaches to improve the existing issues of conventional drug delivery systems. Nanocarriers including natural and synthetic polymeric nanoparticles, metal nanoparticles, liposomes, transferosomes, ethosomes, niosomes, virosomes, cochleate, cubosomes, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), lyotropic liquid crystalline nanoparticles, microemulsions, nanoemulsions, and quantum dots have been investigated for various disease conditions with numerous drug candidates (Girdhar et al., 2018; Martinho et al., 2011; Safari and Zarnegar, 2014; .
Nanoparticles are materials with overall dimensions in the nanoscale, i.e., under 10 to 1,000 nm. From a few decades, it is found that these materials have emerged their multifunctional role in drug delivery with clinical applications which range from diagnostic agents in imaging to carriers for drug delivery and gene delivery into cancerous cells (Dua et al., 2018; Khosa et al., 2018) .
Nanocarriers have been proved effective compared to the conventional approach for targeting the drug candidate to specific organ or tissue. Nanocarriers have been extensively investigated for cancer targeting, central nervous system targeting, tuberculosis, psoriasis, diabetes, Alzheimer, and neurodegenerative diseases (Dua et al., 2018a; Rapalli et al., 2018) .
Due to small size, alteration in surface charge, utilization of penetration enhancers like cell penetrating peptides, nanocarrier-based formulations have been proved as an effective treatment strategy for these diseases. Nanoparticulate systems can be modified to target the site of action, which can improve the efficacy of drugs and minimize the toxic effect of therapeutic agents (Dua et al., 2019) .
Along with these advantages, nanoparticles have certain limitations pertaining to environmental and societal challenges, mainly in concern to toxicity (Murthy, 2007) .
Advantages of nano drug delivery system as follows:
1. Stability of volatile pharmaceutical agents increases. 2. Increase in safety and efficacy compared to conventional drug delivery system. 3. Targeted drug delivery to a specific site of action. 4. Reduced drug resistance. 5. Reduction in particle size enhances the solubility of the drug. 6. The dissolution rate of the formulation increases. 7. Bioavailability of the drug increases. 8. Different types of drug release rates can be achieved. 9. Inter-patient variability decreases. 10. Increase in the stability of poorly stable drugs. 11. Rapid onset of action can be achieved. 12. A low dose of the drug is required to be administered as drug concentration in the targeted tissue is more. 13. Toxic profile of the drug is compromised as dose administered is less.
Polymeric nanoparticles are used for targeted drug delivery with the utilization of various polymers. Polymers are classified into natural and synthetic polymers (Couvreur, 2013) . Naturally occurring biopolymers such as cellulose, chitosan, dextrin, albumin, alginate, and gums have numerous advantages over synthetic substances in terms of biocompatibility, biodegradability, and low immunogenicity (Kumar et al., 2016) . Polymer-based nanoparticles have some drawbacks such as poor drug loading, lack of process scale-up, reproducibility, and stability during storage. In order to overcome these problems, a new approach has come forward, which is "in situ or selfassembled nanoparticles drug delivery systems." This review has covered methods of preparation of traditional nanoparticles, its advantages, challenges, and attempts made to overcome these challenges. Additionally, in situ nanoformulations preparation techniques have also been discussed as a future perspective to overcome the traditional preparation methods for nanoparticles.
CURRENT METHODS OF PREPARATION OF NANOPARTICLES
Several methods for the preparation of nanoparticles were reported in the literature based on the type of materials used in the preparation, such as polymers, lipids, and metals. Some most applied preparation techniques for the polymeric and lipid nanoparticles are discussed in the following section (Paliwal et al., 2014) . A compilation of widely used preparation techniques for polymeric nanoparticles and lipid-based nanocarriers systems are shown in Figure 1 .
Preparation of polymeric nanoparticles

Nanoprecipitation
It is also called a solvent displacement method. This technique is developed by Fessi et al., which includes precipitation of preformed polymers (Nagavarma et al., 2012) . In this technique, the polymer is dissolved in a water-miscible organic solvent like acetone and the polymer solution is diffused into the aqueous medium, which leads to the formation of colloidal suspension either in the presence or the absence of surfactant (Nagavarma et al., 2012). The aqueous phase chosen should be miscible with the solvent and should be a non-solvent for the polymer (Loh et al., 2015) . This method is appropriate for encapsulation of lipophilic drugs (water-miscible solvents) compared to hydrophilic drugs (water-immiscible solvents). In some cases, certain instability may occur when water-miscible solvents are mixed with an aqueous medium, and spontaneous emulsification is not observed. This may happen due to the higher rate of formation of coalescence by the droplets formed. When the interfacial tension between two phases is decreased, rapid diffusion occurs and small-sized droplets of organic solvents are formed, this effect is called as "Marangoni effect" (Crucho and Barros, 2017) . The final particle size and the size distribution of prepared nanoparticles depend upon the nucleation and the growth kinetics which are the controlling factors for this method. The states in which the drug is present in the nanoparticles have a major impact on stability and bioavailability. To enhance the stability of nanoparticle, surfactants could be added to the preparation. Various polymers are investigated in this method, including Polylactic-co-glycolic acid 36, Polylactic acid 43, Polycaprolactone 44, and poly (methyl vinyl ethermaleic anhydride), etc. There are many processing parameters which influence the physicochemical properties of polymeric nanoparticles such as the ratio of organic phase to aqueous phase, the rate of injection of the organic phase, mixing speed, nature, and concentrations of constituents. Due to simple, quick processing, and reproducible results, this method is extensively used. However, there are many challenges for preparation of nanoparticles by means of nanoprecipitation, which include a selection of appropriate drug, solvent, and non-solvent, inefficient encapsulation of hydrophilic drugs, and problem in mixing during nanoprecipitation (Schubert et al., 2011; Xie and Smith, 2010) .
Milling method
In this method, different techniques such as wet milling, milling media, high-pressure homogenization, and cryogenic milling are used for nanoparticle preparation (Loh et al., 2015) . The shear force generated upon impact is the principle involved in size reduction. In wet milling, nanoparticles are produced from the drug particles suspended in liquid medium with other excipient and are milled using beads. This method is suitable for potent drugs and for drugs with high moisture content. Both organic and inorganic compounds can be used in this technology. At the end of milling, nanosuspension is produced which can be transformed into solid dosage form by granulation, freeze drying, and spray drying. Trisenox®, an arsenic compound is a market preparation produced using this method (Miller et al., 2002) . Media milling and high-pressure homogenization are two common top-down approaches for drug nanoparticles production without using beads. For high-pressure homogenization, two types of apparatus can be used, namely, microfluidization and piston-gap homogenization (Keck and Muller, 2006) . The speed of homogenization, nature of the drug, number of cycles, and temperature control the size of nanoparticles. Due to their ease of scale-up, robust processing, economic advantages, and regulatory authority acceptance, it has become a point of research in the past decade. Some of the United States Food and Drug Administration approved products include Rapamune ® , Megace ® , and TriCor ® that were based on media milling technique, and Triglide™ was based on high-pressure homogenization technique (Khinast et al., 2013) . The size and physical stability of prepared nanoparticles depend on milling media, dispersion media, and the stabilizer used. Drawbacks of this technique include contamination of the product with the erosion of the milling material, long milling time, and scale-up problems.
Extrusion method
It is a simple method and is used to convert hydrophobic drugs into nanoparticles in a scalable and inexpensive manner . This technique involves the use of high pressure, shear, and heat which changes the structure of subjected compound like gelatinization, melting, and fragmentation (Song et al., 2011) . This technique converts a liquid stabilized nanosuspensions into solid nanocrystals through hot-melt extrusion combined with an internal devolatilization process. In this method, water from the extruder is removed by devolatilization and polymer is solidified at the outlet. Hot melt extrusion is a continuous process in which raw material is pumped at high temperature and pressure which in turn produce uniform-sized nanoparticles (Maniruzzaman et al., 2012) . This technique can be further utilized for the preparation of hydrophobic nanoparticles using the nanoporous membrane extrusion method. Nanoporous membrane extrusion includes four common strategies which are vesicle extrusion, membrane emulsification, precipitation extrusion, and biological membrane extrusion. These strategies are used in the fabrication of different nanocarriers, such as liposomes, emulsions, nanoparticles, nanotubes, and nanofibers (Guo et al., 2018) . Challenges with this technique are not major but still exists like scale-up problem, the problem in nanomaterial preparation using a small amount of raw material and accumulation of raw material filtration residue at the feeding site of the channel which can block the channel easily (Roy et al., 2009) .
Supercritical fluid technology
It is one of the most prominent techniques in polymeric nanoparticle production because of its advantageous processing parameters such as mild temperature conditions and avoidance of organic solvents. This technique is not only green and novel but is also useful for the enhancement of solubility of poorly soluble drugs, plasticization of polymers, surface modification, nanosizing, and nanocrystal modification and chromatographic extraction (Girotra et al., 2013) . In this technique, fluid is converted into gas with the density of the liquid above its critical temperature and pressure (Sanli et al., 2012) In the preparation of nanomaterials, supercritical CO 2 and H 2 O are extensively used. Under supercritical fluid (SCF) conditions, one can produce nanoparticles with in situ surface modification and controlled size and shape by the use of surfactants, capping agents, and templates. Alteration of surface properties from hydrophilic to hydrophobic and vice versa can be done by using appropriate capping agents (Byrappa et al., 2008; Chattopadhyay et al., 2007) .
There are different methods involved in the SCF technology, they are:
1. Static supercritical fluid process 2. Rapid expansion of supercritical solutions 3. Particles from gas-saturated solutions 4. Gas anti-solvent process Some of the merits of this technique include control on fluid properties, reduction in viscosity, and suitability for temperature sensitive molecules. It has also some drawbacks including the requirement of high-pressure equipment which need high investment and also most of the polymers show poor solubility in SCF (Fattahi et al., 2016) .
Salting-out method
This method came into existence in order to overcome the disadvantages of emulsification-solvent evaporation technique and solvent displacement or nanoprecipitation method for nanoparticle preparation (Mendoza-Muñoz et al., 2012) . It is a modification of the emulsion diffusion technique. In this method, drug and polymer are dissolved in a water-miscible organic solvent like acetone, followed by emulsification into an aqueous gel containing salting-out agent (magnesium chloride, calcium chloride, magnesium acetate, and sucrose) and a colloidal stabilizer. Colloidal stabilizer (polyvinyl pyrrolidone) is added in order to achieve stability for the dispersion phase of the emulsion. A large amount of aqueous medium is added to the emulsion (o/w) so that the diffusion of the solvent into the aqueous phase occurs and nanoparticles are formed. Cross-flow filtration is performed in order to remove the solvent and salting-out agent as they can affect the drug encapsulation efficiency. Advantages of this method include high efficiency, scale-up, and its usefulness for thermolabile substances. Certain disadvantages of this method are its limited applicability to lipophilic drugs and requisite of extensive nanoparticle washing.
Ionic gelation Technique
Ionic gelation method was previously called as ioninduced gelation. This method involves crosslinking of an ionic polymer with a counterionic material, which forms nanoparticles. If the polymer is positively charged, then the counterionic material is negatively charged in order to form cross-links. This crosslinking is due to electrostatic interactions between the polymer and counterionic material. It is followed by ionic gelation due to ionic interactions, which involves the transition of the material from a liquid into gel form at room temperature. In this method, the cluster is formed in the pre-gel phase by reaction of the polymer with a gelling agent. The prepared cluster is then stabilized by complex formation using polyelectrolyte. An example of this process is the formation of pre-gel phase using alginate with calcium which is then stabilized by different polycations, such as chitosan (De and Robinson, 2003; Douglas and Tabrizian, 2005; Sarmento et al., 2007) and polylysine (Rajaonarivony et al., 1993) . Disadvantages of this method include improper surface morphology, fragile particulate system, and high poly dispersibility index (Kunjachan and Jose, 2010; Patil and Chavanke, 2012) .
Sonication method
In this method, nanoparticles are prepared by simply dissolving polymer and drug in an organic solvent. It is then allowed for sonication under appropriate conditions, followed by removal of the solvent by filtration and repeated washings to get drug-loaded polymeric nanoparticles (Shi et al., 2012) . Sonication method is preferred for the dispersion of noninert and non-functionalized metal nanoparticles like Cu, Mn, and Al. Sonication increases the release of metal from metal nanoparticles which can be further accelerated with the addition of solubilizing agents like Bovine serum albumin. Depending upon sonication time, particle agglomeration, metal dissolution, and zeta potential also change to different extents (Pradhan et al., 2016) .
Preparation of lipid nanoparticles
High-pressure homogenization
For the preparation of solid lipid nanoparticles of drugs, high-pressure homogenization is the major technique employed (Corrias and Lai, 2011) . Main advantages of this technique include improved stability of the drug, enhanced drug loading, no use of organic solvents, and large-scale production (Ekambaram et al., 2012) . It can be performed in two ways, i.e., hot homogenization and cold homogenization. A schematic representation of a hot and cold high-pressure homogenization technique for the preparation of lipid nanocarriers is shown in Figure 2 . Hot homogenization is performed for lipophilic drugs and the process is operated at a temperature above the melting point of lipid. Lipid is melted and the drug is added to this, then this drug-loaded lipid is mixed with aqueous phase using a high shear mixer. Quality of pre-emulsion determines the final form of nanoparticles. Lipid nanoparticles are formed upon congealing the nanoemulsion at room temperature. Limitations and challenges of this method include its suitability for the thermostable drug, infiltration of the drug into the aqueous phase, and complications of the crystallization process (Mehnert and Mäder, 2001 ) (Parhi and Suresh, 2012) . Also, during homogenization, drug distribution and loss may occur into the aqueous medium. This method produces particles of low size and narrow particle size distribution. To solve the problems associated with hot homogenization, cold homogenization method has been developed (Naseri et al., 2015) . Cold homogenization is a type of high-pressure milling of suspension, in which lipid microparticles are prepared initially by melting lipid with drug and allowed to solidify quickly using liquid nitrogen or dry ice. The nanoparticles are obtained by homogenization of prepared microparticles below room temperature using high-speed stirring in cold aqueous surfactant. This method yields large sized particles with broad size homogenization (Parhi and Suresh, 2012) .
Solvent emulsification evaporation
In this method, nanoparticles are prepared by dissolving lipid and drug in a volatile organic solvent. Previously, dichloromethane and chloroform were used as solvents, but recently, ethyl acetate is widely used due to its better toxicological profile. The mixture is emulsified in an aqueous solvent containing a stabilizer [polyvinyl alcohol, poloxamer] (Ahlin Grabnar and Kristl, 2011) . Sonication or high-energy homogenization is performed for the formation of emulsion (O/W) with smaller droplet size. The organic solvent is then removed either by stirring or under reduced pressure or by evaporation. This leads to the formation of nanoparticles by lipid precipitation. The nanoparticles are collected by using ultracentrifugation and by washing with distilled water. Experimental parameters, such as processing temperature, method for solvent evaporation, the volume of the aqueous phase, amount of surfactants, and molecular weight of polymer influence the physicochemical properties of prepared nanoparticles (Crucho and Barros, 2017) . The concentration of lipid, surfactant, and co-surfactant in organic phase determines the particle size of prepared nanoparticles. With increasing lipid concentration, particle size increases and with decreasing concentration of polymer, particle size decreases. This method is suitable for thermolabile drugs as it is devoid of thermal stress. This method is limited to lipophilic drugs only and has some scale-up problems (Pinto Reis et al., 2006) . The use of this method is limited due to time consumption and particle coalescence during the solvent evaporation (Fornaguera et al., 2015) .
Emulsification and solvent displacement method
It is a modified method of solvent emulsification evaporation. Here, the lipid and drug are solubilized in a partially water-miscible organic solvent and then it is saturated with water to get a thermodynamic equilibrium between both the liquids. The solvent in the mixture gets diffused into the water as it is partially miscible with water and, as a result, lipid nanoparticles precipitate out from the disperse phase. This method can produce nanoparticles below 100 nm with low polydispersity index. The solvent can be removed from the system either by evaporation or filtration. Use of surfactants will alter the particle size. Non-ionic surfactants yield large particle size compared to ionic surfactants. Use of surfactants in a combination will give a synergistic effect and produce a better particle size. By adding oil like miglyol in an organic phase, nanocapsules can be obtained in place of nanospheres. The size of prepared nanocapsule is influenced by the concentration of oil, type of surfactant, and also the volume of solvent (Moinard-Chécot et al., 2008) . This method yields high encapsulation efficiencies, better reproducibility, no need for homogenization, ease of scale-up, and narrow size distribution. Properties of prepared nanoparticles are influenced by process parameters including polymer and surfactant nature and concentration, type of solvent, agitation speed and time, type of stirrer, the temperature of dilution water, and viscosity of external phase (Bhatia, 2016; Colombo et al., 2001; Kwon et al., 2001 ) Disadvantages of this method include the elimination of high volumes of water from suspension and chances of leakage of the water-soluble drug during emulsification into aqueous external phase.
Challenges in Nanodrug Delivery System
Apart from the numerous advantages, there are certain challenges and limitations for nanotechnology, some of them are discussed as follows: (Desai, 2012; Jindal et al., 2017; Wei et al., 2012) .
1. There are no regulatory standards for examination or characterization of nanoparticle medicines. 2. Problems in scale-up production of nanoparticles and lack of reproducibility in size and size distribution of nanoparticle. 3. Optimization of surface properties for targeted delivery and minimum non-specific adsorption. 4. Need for careful design and engineering for maintaining nonspecific cytotoxicity at a low level. 5. At the manufacturing scale, the process becomes expensive and there is a compromise in the yield and morphology of prepared nanoparticles.
Most of these challenges arise during the scale-up process from laboratory scale to manufacturing scale. Some of the effects occurring due to alteration in size, size distribution, and surface properties are discussed below. Particle size and size distribution are the most important characteristics of nanoparticle medicine as they significantly influence the pharmacokinetic properties and safety of the formulation. A rapid renal clearance occurs if the particle size is smaller than 20-30 nm, whereas uptake by reticuloendothelial cells, liver, bone marrow, and spleen increases if the particle size is greater than or equal to 200 nm.
Nanoparticle surface properties will significantly influence the behavior and interaction of nanoparticles with proteins and cells after entering into the body. Surface properties, such as charge, hydrophobicity, and functional groups, are associated with stability and opsonization process after entering into blood circulation. In the blood, these nanoparticles bind with various components, such as albumin, fibrinogen, IgG, and apolipoproteins through a process called opsonization which leads to clearance of nanoparticles by macrophages due to activation of the alternate pathway. Particles with the hydrophobic surface are directly taken up by macrophages without opsonization process.
Some of the desired properties of nanoparticles are lost during the process of scale-up. For example, during scale-up of a process using the emulsion method, it was noted that with the increase in the impeller speed and agitation time, there is a decrease in the particle size without any change in entrapment efficiency.
Self-assembled nanoparticles drug delivery system
In order to avoid these complications arising during scale-up, there is a novel approach of drug delivery that is "in situ" or "self-assembled" nanoparticles drug delivery system. This is the process in which nanoparticles are formed after administration of formulation into the body. As this concept is at its very juvenile stage, a limited formulation approaches have been investigated where different types of polymers, surfactants, or novel process are employed in order to prepare a pre-concentrate of drug formulation which on entering into an aqueous medium (GI fluid, blood) forms the nanoparticles. The in situ nanoformulations can be the futuristic approach in nanocarriers to overcome the problems associated with the scale-up process and also minimize the cost of production. These self-assembled nanoformulations have been studied for delivery of antiviral drugs, anticancer drugs, and antihyperlipidemic.
Various approaches have been attempted in order to deliver the drug through in situ or self-assembled nanoparticles drug delivery system. Jindal et al. (2017) prepared in situ hybrid nano drug delivery system (IHN-DDS) of nevirapine (NVP) for simultaneous targeting to multiple viral reservoirs. Initially, preconcentrate of drug, lipid, and surfactant was prepared. They have used poloxamer 188 at different concentrations as a surfactant, either stearic acid or polyglyceryl-6-distearate as lipid, and N,Ndimethylacetamide as a solvent. Prepared preconcentrate was diluted with distilled water in order to obtain IHN-DDS. The mean particle size was found to be <200 nm in size with zeta potential of -26.8±2.1 mV, which indicated higher colloidal stability of insitu nano preparation. It was found that changes in poloxamer concentration from 0.1% w/v to 1% w/v influenced the particle size and % entrapment efficiency (EE). In vitro release studies stated that 35% of the drug showed burst release from HN-DDS in the first 1 hour, which may be due to surface entrapment or free drug. Later it was observed that the release followed slow and sustain form up to 24 hours. Stability studies for 6 months showed good stability with no significant change in particle size distribution. In vivo biodistribution studies were performed in Sprague-Dawley rats, which demonstrated 6 folds higher plasma concentration compared to free NVP solution at 1 hour. Increased drug accumulation by 6.1, 5.8, and 3.7 folds was observed in liver, spleen, and brain, respectively, at 1 hour. In vitro and in vivo results demonstrated that design in situ nanopreparation can provide desired physicochemical dispersion properties after administration and can provide selective targeting to the major organ with appropriate modifications. Lin et al. (2011) prepared and characterized the in situ formation of fenofibrate nanocrystals using a self-micro emulsifying drug delivery system (SMEDDS). The formulation was composed of Myritol ® , surfactant mixture of D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS), and either tween 20 or tween 80 at various proportions of oil and surfactant mixture. Here, they employed the SMEDDS method in order to prepare a preconcentrate of drug, surfactant, oil, and cosolvents. The formed preconcentrate upon entering into water or pH 1.2 simulated gastric acid will convert into O/W microemulsion with nanosized droplet range. The physicochemical characterization shows that the prepared formulations were in the nanosize range, i.e., 200 nm. Formulations containing tween 80 series showed faster release rate and complete release compared to tween 20 with an insignificant difference between them. They also compared designed nanoformulation with marketed formulation Tricor ® for relative bioavailability. It was found that relative bioavailability was enhanced by 1.14-1.22 folds. Kapse et al. (2012) prepared tamoxifen citrate (TMX) pre-concentrate using self nanoprecipitation method for enhancing bioavailability. They have prepared a pre-concentrate of TMX, kollidon SR as polymer and binary surfactant mixture of aerosol OT (AOT) and tween 80 or mirj-52 or Pluronic-F68 (PF-68). The pre-concentrate upon dilution with aqueous media converted into polymeric nanoparticles of TMX. Results showed that particle size and entrapment efficiency were highly influenced by the type and concentration of the surfactant used. Non-ionic surfactant yielded larger particle size of >1 µm with low EE of <30%, whereas in case of anionic surfactant, AOT produced EE of >80% due to ionic complexation with TMX. Binary surfactant mixture produced better results compared to individual components. Due to the interaction of binary surfactant and a simultaneous decrease in surface tension result in nanosized particles. At 1% and 5% v/v of tween 80, particle size was found to be 238 ± 2.1 nm and 108 ± 2.1 nm and with Mirj-52, 208.7 ± 2.5 nm and 116.1 ± 3.2 nm, respectively. Higher EE of >80% and low particle size was obtained using tween 80 (1%v/v) and AOT (1.5% v/v) combination. Differential scanning calorimetry and X-ray powder diffraction results confirmed the conversion of a crystalline form of TMX into amorphous form in nanoformulation. TEM image showed the spherical shape and nanosize of the obtained TMX nanoparticles. Bioavailability studies on rat showed an increase in relative bioavailability of TMX nanoparticles by 165.61% compared to free TMX, which may be due to the direct intake of nanoparticles by lymphatic circulation.
Preparation of self-assembled nanocarriers
Building blocks
There are specific polymeric materials available for building up self-assembled nanocarrier, which can be natural or synthetic (Irby et al., 2017; Kohli et al., 2014; LaManna et al., 2012) . Many synthetic polymeric nanoformulations have been studied because of their flexibility, countless availability, and ability to tailor with different sizes and morphology and modification with functionality (Mora-Huertas et al., 2010) . Water dispersive polymers with hydrophilic side chain and hydrophobic backbone as well as amphiphilic copolymers are widely used in the preparation of self-assembled nanocarriers.
Recently, the application of natural, synthetic, and recombinant proteins have increased in the drug delivery system due to their many advantages like biocompatible, biodegradable, and high degree of self-assembly. Proteins as building block provide the unique option of the delivery system with a properly defined internal and external surface, undeviating morphology, and wide options of shapes and sizes ranging from 18 to 500 nm. Natural polysaccharides have also been emerging as a natural polymer for nanocarriers. Hybrid material by using two or three different types of material increases the choice of building block which can be used for maintaining the properties of nanoformulation.
Encapsulation of drug
There are different methods for encapsulation of drug depending upon the nature of the drug and the type of nano preparation. Carrier molecule can be used to find which drug can be covalently attached and assembled inside the nanocarrier like polymer-drug conjugates. Proteins and gene are delicate in nature; therefore, they are capsulated inside the nanocarrier to maintain their stability and prevent them from metabolism. For attachment of proteins to delivery molecules, bioconjugate reactions are highly advisable to retain the activity of the protein as these reactions are very specific and there are fewer chances of structural changes in proteins (Beck et al., 2017; Sivaram et al., 2018) . Coulombic interactions can be used for gene therapy and gene delivery as this provides a steady force which prevents undesired leaking. A hydrogen bond is another option for encapsulation. Although hydrogen bond is less advisable in the aqueous solution, here the drug is out of the reach of water; therefore, hydrogen bonded drug can be stably encapsulated inside the carrier.
Drug Release from Self-Assembled Nanocarriers
Like building up, drug release is also a very important part in self-assembled nanomedicines. Depending upon the interaction of nanocarrier with the surrounding environment, releasing modes can be categorized into two kinds; nonstimuliresponsive release and stimuli-sensitive release.
Non-stimuli-responsive release
In this case, the carrier would sharply break and blowout all the drugs at once. In sustained release nanoformulation, it will take more time because the time taken for detachment and dispersion of drug and then continuous erosion of carrier is more. These carriers may be biodegradable or non-biodegradable. Nanoparticles in which non-biodegradable carrier like polystyrene or poly(methyl methacrylate) is being used, are fabricated as porous structures on which drug first attaches, then detaches and, finally, diffuses out from it. Osmotic pressure plays an important role in drug release as it acts as a driving force for the drug (Keraliya et al., 2012) . In biodegradable nanocarriers, hydrolyzable bonds are introduced to release the drug from the carrier. The main disadvantage of nonstimuli-responsive release is that the drug may release before reaching to the target site and this system is uncontrollable.
Stimuli-responsive release
The controllable release of the drug can be achieved by incorporating responsive groups in nanoparticles which breaks in the presence of certain stimuli (Jin et al., 2018) . On breakage, whole structure disrupts and drug releases out. Based on the stimuli exercised, they can be divided as internal stimuli and external stimuli. When there is variation in the target site such as a change in pH, different expression of enzymes, other molecules in tissue, and abnormal redox environment, then internal stimuli is originated.
pH stimuli
Due to the Warburg effect, tumor cell proliferates at a high rate and there is a deficiency of nutrients which results in accelerated glycolysis and lactic acid accumulation, leading to lower environmental pH (Estrella et al., 2013) . This difference in pH acts as an internal stimulus which activates the drug release. pH stimuli cause hydrolysis due to which either bond breaks and structure degenerates or there can be a change in molecular interaction because of protonation, which, in turn, causes breakage of the assembly. Different kinds of moieties which are cleaved in acidic environments, such as hydrazine, acetal, amine, orthoester, boronic acid ester, and vinyl ether, have been introduced and studied. pH difference between intracellular endosomes/lysosomes and extracellular matrix is more than that of the extracellular matrix of normal and cancer cells, which is more advantageous for drug release (Yameen et al., 2014) . Nanocarriers are transported into lysosomes, where the carrier is lysed and the drug gets released.
Redoxstimulus
Glutathione (GSH) serves as a general reductant for cells and also plays other functions including bioactivity maintenance, redox state maintenance, and xenobiotics detoxification. GSH concentration is a thousand times more inside the cell than that of the extracellular matrix. In tumor cells, the concentration of GSH increases additionally. Nanoparticulate systems containing carriers with disulfide and diselenide bond can be used to deliver the drug in these tumors because these bond can be broken by GSH (Ortega et al., 2011) .
Reactive oxygen species (ROS) are oxygen-containing highly reactive chemical species like superoxide (O2−), hydroxyl radical (HO•), nitric oxide (NO•), peroxyl radicals (ROO•), hydrogen peroxide (H 2 O 2 ), ozone/trioxygen (O 3 ), and other high-reacting substances. ROS are vital for cellular activity because they are involved in all processes for cell differentiation, propagation, and transferring of intracellular vesicles. In cancer cell, ROS concentration increases which lead to an alteration in the redox state of the tumor cell. Carriers containing selenide can disrupt tumor cells due to the higher concentration of ROS which oxidizes selenide to selenoxide which increases hydrophilicity and this causes the drug release. Carriers with oxidative cleavable moieties, such as thioketals, boronic esters, and polyprolines release drugs easily in the presence of ROS (Zeng et al., 2016) .
Temperature stimuli
Targeted delivery of nanoparticle is mainly required for tumor cells where there is abnormal temperature due to many reasons such as accelerated metabolic reactions, accelerated cell proliferation, and leukocyte infiltration (Hurwitz and Stauffer, 2014) . In some experiment, it was found that the release of the encapsulated drug was more when it was heated up to phasetransition temperature (T m ). With the change in temperature, physical state and mobility of lipid changes like below T m lipid molecules remain in gel state as these molecules are well-ordered and get condensed and remain immobile while at temperature reaching to T m , head group of molecules becomes mobile and its state changes from gel to the liquid crystalline phase. At exact T m temperature, both liquid and solid lipid phase exist and create interphase through which drug leaks causing an increase in permeation.
Introduction of temperature-sensitive polymer like poly(N-isopropylacrylamide) (p-NIPAM), poly(vinyl ethers), and their derivatives in nanocarrier is another way of producing temperature responsive delivery system as they can change the conformations according to the change in temperature. Stability of polymer depends on their low critical solution temperature (LCST). Below this temperature, the polymer is stable but as the temperature increases above LCST, polymer chain gets condensed and results in the destruction of the nanocarrier. LCST of any polymer can be adjusted according to the requirement of targetspecific drug release by copolymerization with other monomers having different hydrophilicity and hydrophobicity (Zhao et al., 2015) .
Enzyme and other biomolecules stimuli
When carrier contains linker which can be cleaved by enzymes, they behave as a substrate for enzymes and release drugs after enzymolysis. There are many enzymes, for example, protease, esterase, phospholipase, and many more which break covalent bonds of biomacromolecules like phospholipids and act as a decomposer. Along with enzymes, some small molecules such as Adenosine-5ʹ-triphosphate (ATP) can also act as triggers. ATP is an essential biomolecule present in high concentration inside the cell than that of the extracellular environment. This difference in concentration provides an opportunity to develop ATP-responsive carriers (Mo et al., 2014) .
Light stimuli
It is a type of external stimulus which can trigger accurate drug release at the site of action. Upon light irradiation, structural transformation occurs in nanoparticles and it gets collapsed. At a particular wavelength of light, the bond gets cleaved and there occur configurational and electrostatic changes, which, in turn, disrupt the nanocarrier moiety. Most of the triggered transitions are based on UV to visible light with a short wavelength. However, the major problem in light triggered drug release is shallow penetration in tissues. Near-infrared (NIR) provides an advantage over UV light as it can go deeper into the tissue. Other than NIR, bioluminescence is another option to solve the problem of penetration by UV light, and it also avoids the need of an external source for radiation as bioluminescence of luminol can be absorbed by molecules. To overcome the problem of poor penetration, longpersistent luminescence material can also be used (Abdurahman et al., 2016; Fan et al., 2017; Wang et al., 2017) .
Other stimuli
Other than above-mentioned stimulus, magnetic field response, electric field response, and ultrasound stimuli are other external mechanisms (Manouras and Vamvakaki, 2017) to trigger drug release. Combination of both internal and external stimuli provides several approaches for responsive drug release.
Challenges of Self-Assembled Nanocarriers
Despite having eminent properties, such as selective targeting, reducing the side effects of conventional therapy, enhancing the pharmacokinetic profile of the drug, and improved efficiency of drug delivery, there are some limitations of selfassembled nanocarriers which restrict its industrialization. Many nanocarriers are found to be toxic in clinical observations but this drawback can be solved by adjusting the parameters of nanoparticles, including shape, size, composition, and surface modification . Nanocarriers are used to enhance the permeability of drugs but this can result in the accumulation of the drug in tumor tissues. This prolongs accumulation is decreased in delivery efficacy of the drug to tumor site along with a reduction in the improvement of the overall survival of patients (Nakamura et al., 2016) .
When these nanocarriers are delivered into the biological system, it interacts with biomolecules in a nonspecific manner which makes the delivery process unpredictable (Mahmoudi et al., 2011; Monopoli et al., 2012) . In a biological environment, nanocarrier is covered with several biomolecules after reaching there, which make uncertain alterations in its size, stability, and surface properties, which, in turn, changes the properties of nanoformulation related to its distribution, cellular uptake, drug effect, and toxicity.
Additionally, there are major challenges in scale-up and reproducibility. Extensive research studies are under progression for different categories of drugs with feasible methods to improve the existing problems of these drugs and to provide improved therapeutic efficacy (Table 1) . There is great hope with advanced and improved technology and composition for nanocarriers preparation which can provide selective delivery and minimize the adverse reactions with an affordable cost of therapy. Additionally, regulatory agencies are also working on quality and safety aspects of nanocarriers-based delivery systems.
continued Table 1 . Nanoformulations prepared with different techniques.
Method of preparation Type of nanoformulation Drug References
Milling Method Nanocrystal Niclosamide (Anthelmintic drug) (Ye et al., 2015) Amorphous ternary cyclodextrin nanocomposites of telmisartan Telmisartan (Sangwai and Vavia, 2013) Nanocrystals embedded in microparticles Indomethacin (Laaksonen et al., 2011) Ophthalmic Nanosuspension Miconazole (Antifungal) (Cerdeira et al., 2010) Polymeric microspheres and drug-polymer composites Ketoprofen (Kluge and Mazzotti, 2012) Lipid Nanoparticle Quercetin (Topical) (Scalia et al., 2013) Intravenous Lipid Emulsion Tanshinone IIA (Chu et al., 2012) Solvent Emulsification Evaporation Nanostructured lipid carrier Ketoprofen (Müller et al., 2007) Lipid Nanoparticle Lercanidipine HCl (Ranpise et al., 2014) Nanoparticle Bovine albumin (Häuser et al., 2015) Lipid polymer nanoparticle Amoxicillin (Cai et al., 2015) Nanoprecipitation Nanoparticle Pioglitazone Hydrochloride (Canchi et al., 2018) Self-assembled lipid-polymer hybrid nanoparticles Mitomycin C (Garg et al., 2015) Lipid polymer nanoparticle Indocyanine green (Zhao et al., 2014) Nanoparticles loaded with small interference RNA DNase I (Cui et al., 2014) Solvent Emulsification Diffusion
Pentapeptide grafted nanostructured lipid carriers Dexamethasone Nanostructured lipid carrier Isoliquiritigenin ( Zhang et al., 2013b) Protein-free nanostructured lipid carrier Lovastatin (Gu et al., 2011) Nanostructured lipid carriers Gentiopicroside ( Zhang et al., 2013a) Nanostructured Lipid Carriers Paclitaxel (Emami et al., 2012) Nanostructured lipid carriers Celastrol Nanostructured lipid carriers Voriconazole (Waghule et al., 2019) 
High-Pressure Homogenization
Solid lipid nanoparticles and nanostructured lipid carriers Bromidine base (El-Salamouni et al., 2015) Nanostructured lipid carrier Lornoxicame Nanostructured lipid carriers Quercetin (Beloqui et al., 2014) Hybrid Nanoparticle UvinulT 150 (Tolbert et al., 2016) Nanostructured lipid carriers Thymoquinone (Abdelwahab et al., 2013) Nanostructured Lipid Carriers Docetaxel (Choi et al., 2016) Nanostructured lipid carriers β-Elemene (Shi et al., 2013) Nanostructured lipid carriers Fenofibrate Lipid-polymer hybrid nanoparticles Dextran Lipid-polymer hybrid nanoparticles Vancomycin (Seedat et al., 2016) Hydroxyapatite nanoparticles Methylprednisolone (Jafari et al., 2016) Extrusion Nanoparticle Anacetrapib (Harmon et al., 2016) Self-emulsifiable nanocomposites Cupric-sulfate (Koo et al., 2018) Solid dispersion Naproxen (Haser et al., 2017) Nanocomposites Zinc sulfate monohydrate (Lee et al., 2017) Super Critical Fluid Nanoparticles Cefquinome (Kefeng et al., 2015) Solid lipid nanoparticles Indomethacin (Chattopadhya et al., 2007) Solid lipid nanoparticles Ibuprofen (Akbari et al., 2015) Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) nanoparticles Bortezomib (Demirdöğen et al., 2018) Nanosuspension Stearic acid (Campardelli et al., 2013) CONCLUSION Due to the inability of conventional formulation in targeting the desired site and associated formulation problems, nanoformulations, such as liposomes, dendrimers, SLNs, NLCs, microemulsions, nanoemulsions, quantum dots, and so on have been developed. Nanoformulations proved advantages like enhanced bioavailability, site-specific delivery, improved stability, and reduced side effects over traditional form of delivery. However, due to certain limitations of nanoformulations such as scale-up issues, stability concern, batch reproducibility, cytotoxicity at low levels, and the problem with surface characterization, in situ or self-assembled nanocarriers system became an attractive strategy for industrial acceptance. In situ nanoformulation approach has successfully overcome the drawbacks of traditional nanoformulations and also showed advantages over complex nano composition methods which produce different sizes of nanoparticles. As these nanomedicines are in their infancy stage, there are many challenges which are limiting its large-scale production. It is expected that as the number of research studies in this area increases, the formulations from laboratory scale will transcend to market in the near future for therapeutics and clinical purpose. By exploring more about it, the present challenges can be resolved and then more advanced medication can come in the market targeting better efficacy and patient acceptability.
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